Cover Image
市場調查報告書

糖尿病藥物的調查

Diabetes Drugs Survey

出版商 TriMark Publications 商品編碼 353580
出版日期 內容資訊 英文 220 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
糖尿病藥物的調查 Diabetes Drugs Survey
出版日期: 2016年01月31日 內容資訊: 英文 220 Pages
簡介

糖尿病的蔓延階段性擴大,帶來新的迫切感。

本報告提供糖尿病藥物調查分析,現在使用中的一般治療方法,未來治療所使用的新興技術等系統性資訊。

第1章 概要

第2章 簡介

  • 糖尿病的人口統計
    • 全球
    • 美國
  • 糖尿病的經濟學
    • 全球糖尿病成本
    • 美國的糖尿病成本

第3章 關於糖尿病

  • 糖尿病預備軍
  • 代謝症候群
  • 糖尿病和炎症
  • 糖尿病的診斷
  • 糖尿病的進展
  • 肥胖和糖尿病
  • 第二型糖尿病的併發症和合併症

第4章 製藥產業和抗糖尿病藥物市場

  • 全球製藥產業
  • 糖尿病治療藥整體市場的市場規模與成長率
  • 糖尿病藥物概要

第5章 非胰島素抗糖尿病藥物產品、市場

  • 非胰島素抗糖尿病藥物市場推動因素與趨勢
  • Meglitinides
  • 雙胍類(Biguanides )
  • 胰島素增敏劑
  • Alpha-Glucosidase Inhibitors
  • Amylin類比等

第6章 胰島素市場

  • 胰島素市場主要企業市場佔有率
  • 專利到期
  • 胰島素生技仿製藥
  • 革新策略
  • 胰島素治療概要
  • 短時間作用型胰島素注射液市場
  • 速效型胰島素類似物市場等

第7章 新興抗糖尿病技術、產品

  • 抗糖尿病藥物市場預測
  • 人工胰臟
  • 胰島素產活細胞
  • 預混合升糖素
  • 抗肥胖藥
  • 胰島素
  • 胰島素和抗糖尿病藥物的組合

第8章 市場趨勢、課題、策略性選擇

  • 概要
  • 糖尿病藥物市場趨勢
  • 糖尿病市場課題
  • 策略性選擇
  • FDA對抗糖尿病藥物開發的指南
  • 近來產業活動

第9章 企業簡介

圖表

目錄
Product Code: TMRDIAS16-01

As the diabetes epidemic escalates, a new sense of urgency has taken hold. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization, as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. This report evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes in the future.

Table of Contents

1. Overview

  • 1.1. Statement of Report
  • 1.2. About this Report
  • 1.3. Scope of the Report
  • 1.4. Methodology
  • 1.5. Executive Summary

2. Introduction

  • 2.1. Demographics of Diabetes
    • 2.1.1. Worldwide Diabetes
    • 2.1.2. U.S. Diabetes
  • 2.2. Economics of Diabetes
    • 2.2.1. Worldwide Costs of Diabetes
    • 2.2.2. Costs of Diabetes in the U.S.

3. Understanding Diabetes

  • 3.1. Pre-Diabetes Syndrome
  • 3.2. Metabolic Syndrome
    • 3.2.1. Prevalence of Metabolic Syndrome
    • 3.2.2. Management of Metabolic Syndrome
    • 3.2.3. The Debate Regarding Metabolic Syndrome
  • 3.3. Diabetes and Inflammation
  • 3.4. Diagnosis of Diabetes Mellitus
  • 3.5. Progression of Diabetes
  • 3.6. Obesity and Diabetes
  • 3.7. Complications and Co-Morbidities in Type 2 Diabetes
    • 3.7.1. Preventing Complications and Co-Morbidities in Diabetes

4. Pharmaceutical Industry and the Anti-Diabetes Drug Market

  • 4.1. The Worldwide Pharmaceutical Industry
    • 4.1.1. Pharmaceutical R&D Spending by Type, Growth Rate and Expenditure
    • 4.1.2. Global Pharmaceutical Market
  • 4.2. Overall Diabetes Drug Market Size and Growth
    • 4.2.2. Sales Forecast for the Global Anti-diabetes Drug Market
  • 4.3. Diabetic Medications Overview
    • 4.3.1. Recent Trends in Diabetic Drug Usage
    • 4.3.2. Market Influence Factors

5. Non-Insulin Anti-Diabetes Products and Market

  • 5.1. Non-Insulin Anti-Diabetes Drug Market Drivers and Trends
    • 5.1.1. Market Share and Forecast of Non-Insulin Anti-Diabetic Drugs
    • 5.1.2. Latest Additions to the U.S. Non-Insulin Diabetes Drug Market
    • 5.1.3. GLP-1 Market Revenue, Market Share, Key Players
    • 5.1.4. DPP-4 Inhibitor Market Revenue, Market Share and Key Players
    • 5.1.5. SGLT-2 Inhibitor Market Revenue, Market Share and Key Players
  • 5.2. Sulfonylureas
  • 5.3. Meglitinides
  • 5.4. Biguanides
  • 5.5. Thiazolidinediones (TZDs)
  • 5.6. α-Glucosidase Inhibitors
  • 5.7. Amylin Analog
  • 5.8. GLP-1 (Glucagon-like Peptide) Analogs and Agonists/Incretin Mimetics
    • 5.8.1. Byetta (Exenatide)
    • 5.8.2. Bydureon (Exenatide LAR)
    • 5.8.3. Victoza (Liraglutide)
    • 5.8.4. Tanzeum (Albiglutide)
    • 5.8.5. Trulicity (Dulaglutide)
  • 5.9. DPP-IV Inhibitors
    • 5.9.1. Januvia (Sitagliptin)
    • 5.9.2. Onglyza (Saxagliptin)
    • 5.9.3. Tradjenta (Linagliptin)
    • 5.9.4. Galvus (Vildagliptin)
    • 5.9.5. Nesina (Alogliptin)
    • 5.9.6. Marizev (Omarigliptin)
  • 5.10. SGLT-2 Inhibitors
    • 5.10.1. Invokana (Canagliflozin)
    • 5.10.2. Farxiga (Dapagliflozin)
    • 5.10.3. Jardiance (Empagliflozin)
    • 5.10.4. Suglat (Ipragliflozin)
    • 5.10.5. Lusefi (Luseogliflozin)
  • 5.11. Fixed Dose Combination Therapies on the Market
  • 5.12. Antidiabetic Drug Options for Youth with Recent-Onset Type 2 Diabetes Scarce
  • 5.13. Comparisons of the Anti-Diabetes Drugs
  • 5.14. Non-Insulin Anti-Diabetes Products in the Pipeline
    • 5.14.1. Novel GLP-1 Agonists and Analogs
    • 5.14.2. Novel DPP-IV Inhibitors
    • 5.14.3. Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitors
  • 5.15. Emerging Anti-Diabetes Targets and Drugs in the Pipeline
  • 5.16. Novel Approaches to Finding New Drug Targets

6. Insulin Markets

  • 6.1. Major Players and Market Share in the Insulin Market
  • 6.2. Patent Expirations
  • 6.3. Insulin Biosimilars
    • 6.3.1. Regulatory Avenues for Biosimilar Approval
    • 6.3.2. Insulin Biosimilars on the Market
      • 6.3.2.1. Abasaglar (formerly Abasria) and Basaglar
      • 6.3.2.2. Other Biosimilars
      • 6.3.2.3. Key Issues for Insulin Biosimilars
  • 6.4. Innovation Strategies
  • 6.5. Overview of Insulin Therapeutics on the Market
    • 6.5.1. Recommendations for Insulin Initiation and Administration
  • 6.6. Short-Acting Human Insulin Market
  • 6.7. Rapid-Acting Insulin Analog Market
    • 6.7.1. Ultra Fast-Acting Insulins in Development
  • 6.8. Intermediate-Acting Insulin Market
  • 6.9. Long-Acting Insulin Market
    • 6.9.1. Lantus-Sanofi's Insulin Blockbuster
    • 6.9.2. Toujeo-Sanofi's Bid to Maintain Insulin Market Share
    • 6.9.3. Levemir Market
    • 6.9.4. Tresiba Approved for the U.S. Market
    • 6.9.5. Lantus Biosimilars
      • 6.9.5.1. Abasaglar (formerly Abasria) and Basaglar
      • 6.9.5.2. Other Biosimilars
  • 6.10. Insulin Mixtures
  • 6.11. Pipeline Insulins in Development
    • 6.11.1. BIOD-531 (Biodel)
    • 6.11.2. Xultophy (Novo Nordisk)
    • 6.11.3. LixiLan (Sanofi)
    • 6.11.4. rHUPH20 and Insulin (Halozyme)
    • 6.11.5. FIAsp (Novo Nordisk)
    • 6.11.6. BIOD-238, BIOD-250, and BIOD-351 (Biodel)
    • 6.11.7. InsuPatch and InsuPad (Insuline Medical)
    • 6.11.8. MK-1293
    • 6.11.9. Smart Insulins
  • 6.12. Non-Invasive Insulin Delivery
    • 6.12.1. Inhaled Insulin
      • 6.12.1.1. Afrezza
      • 6.12.1.2. Dance Pharmaceuticals and Aerogen (Dance-501)
      • 6.12.1.3. A Chronicle of Inhaled Insulins
    • 6.12.2. Oral Insulin
    • 6.12.3. Transdermal Insulin
  • 6.13. Barriers for Non-Injected Insulin
  • 6.14. Patient Potential for Non-Injected Insulin
  • 6.15. Insulin Delivery Devices
    • 6.15.1. Insulin Pens
    • 6.15.2. Injections Aids
      • 6.15.2.1. Automatic Injectors
      • 6.15.2.2. Syringe Magnifiers
      • 6.15.2.3. Injection Ports
    • 6.15.3. Insulin Jet Injectors
    • 6.15.4. Insulin Pumps
      • 6.15.4.1. External Insulin Pumps
      • 6.15.4.2. Animas OneTouch Ping
      • 6.15.4.3. Animas Vibe
      • 6.15.4.4. Accu-Chek Combo Insulin Pump System (Roche)
      • 6.15.4.5. MiniMed Paradigm Real-Time Revel (Medtronic)
      • 6.15.4.6. MiniMed 530G with Enlite (Medtronic)
      • 6.15.4.7. Insulet Omnipod
      • 6.15.4.8. DANA IIS (Sooil)
      • 6.15.4.9. t:flex (Tandem Diabetes Care)
      • 6.15.4.10. t:slim (Tandem Diabetes Care)
      • 6.15.4.11. Snap (Asante)
    • 6.15.5. Insulin Infusion Sets
    • 6.15.6. Insulin Patch Pumps in Development or Only Available Outside the U.S.
    • 6.15.7. Implantable Insulin Pumps
    • 6.15.8. Insulin Pump Market Share
    • 6.15.9. Drivers of Demand for Pumps
  • 6.16. Market Forecasts for Insulin Administration Technologies

7. Emerging Anti-Diabetes Technologies and Products

  • 7.1. Projections for the Anti-Diabetes Drug Market
  • 7.2. Artificial Pancreas
    • 7.2.1. MiniMed 530G System
    • 7.2.2. Animas Vibe System
    • 7.2.3. Next Generation Medtronic Artificial Pancreas Systems (MiniMed 640G)
    • 7.2.4. FDA's Artificial Pancreas Guidance Document
  • 7.3. Insulin-Producing Cells
    • 7.3.1. Gene Therapy
    • 7.3.2. Cell Therapy Companies for Diabetes
      • 7.3.2.1. ViaCyte (formerly Novocell, Inc.)
      • 7.3.2.2. Sernova
      • 7.3.2.3. Semma Therapeutics
  • 7.4. Pre-Mixed Glucagon for Self-Treating Hypoglycemia
  • 7.5. Anti-Obesity Drugs to Prevent or Delay Development of Type 2 Diabetes
    • 7.5.1. Xenical (Roche)
    • 7.5.2. Qsymia (Vivus)
    • 7.5.3. Belviq (Arena Pharmaceuticals)
    • 7.5.4. Contrave (Orexigen Therapeutics)
    • 7.5.5. Saxenda
    • 7.5.6. Anti-Obesity Drugs in Development
  • 7.6. Insulin and Anti-Diabetes Drug Combinations
    • 7.6.1. Xultophy (Novo Nordisk)
    • 7.6.2. LixiLan (Sanofi)

8. Market Trends, Challenges and Strategic Options

  • 8.1. Overview
  • 8.2. Diabetes Drug Market Trends
    • 8.2.1. Overview
    • 8.2.2. Emergence of Therapeutics with Improved Administration Characteristics
      • 8.2.2.1. Barriers to the Initiation of Insulin Therapy in Type 2 Diabetics
    • 8.2.3. Increasing Prevalence of Obesity
    • 8.2.4. Consumer Preference Drives Product Development in Invasive Technology Segment
  • 8.3. Diabetes Mellitus Market Challenges
    • 8.3.1. Overview
    • 8.3.2. Patent Expirations
    • 8.3.3. Market Prospects of Inhalable Insulin
  • 8.4. Strategic Options
    • 8.4.1. Developing Countries are Key Markets for Growth
    • 8.4.2. Consumer-Driven Marketing Campaigns
    • 8.4.3. Strategies for Successful New Product Launches
    • 8.4.4. Collaborations and Strategic Alliances
  • 8.5. FDA Guidelines for Developing Anti-Diabetic Drugs
  • 8.6. Recent Industry Activity

9. Company Profiles

  • 9.1. A. Menarini
  • 9.2. Abbott Laboratories
  • 9.3. Abbvie
  • 9.4. Amgen
  • 9.5. Amylin Pharmaceuticals (bought by Bristol-Myers Squibb)
  • 9.6. Animas (part of Johnson & Johnson)
  • 9.7. Asante
  • 9.8. Astellas Pharma, Inc.
  • 9.9. AstraZeneca PLC
  • 9.10. Bayer
  • 9.11. Becton, Dickinson and Company
  • 9.12. Biocon
  • 9.13. Biodel
  • 9.14. BodyMedia
  • 9.15. Boehringer Ingelheim
  • 9.16. Bristol Myers Squibb
  • 9.17. Cellnovo
  • 9.18. CeQur
  • 9.19. ConjuChem
  • 9.20. Daiichi Sankyo
  • 9.21. Dance Biopharm
  • 9.22. Debiotech
  • 9.23. DexCom
  • 9.24. Echo Therapeutics, Inc.
  • 9.25. Eli Lilly
  • 9.26. FIFTY50. Medical, Inc.
  • 9.27. Flamel Technologies
  • 9.28. Generex Biotechnology Corporation
  • 9.29. GlaxoSmithKline PLC
  • 9.30. Halozyme Therapeutics
  • 9.31. Insulet
  • 9.32. Insuline Medical Ltd.
  • 9.33. Intarcia Therapeutics, Inc.
  • 9.34. Janssen Research & Development
  • 9.35. Johnson & Johnson
  • 9.36. Kowa Pharmaceuticals
  • 9.37. Lexicon Pharmaceuticals
  • 9.38. MannKind Corporation
  • 9.39. Medipacs
  • 9.40. Medtronic
  • 9.41. Merck & Company, Inc.
  • 9.42. Mitsubishi Tanabe Pharma Corporation
  • 9.43. Novartis
  • 9.44. Novo Nordisk
  • 9.45. Oramed Pharmaceuticals
  • 9.46. Orexigen Therapeutics, Inc.
  • 9.47. Owen Mumford
  • 9.48. PhaseBio Pharmaceuticals
  • 9.49. Pfizer
  • 9.50. Prometheon Pharma
  • 9.51. Roche Diagnostics
  • 9.52. Sanofi
  • 9.53. Sernova
  • 9.54. Smiths Medical
  • 9.55. SOOIL Development
  • 9.56. Taisho Pharmaceuticals
  • 9.57. Takeda
  • 9.58. Tandem Diabetes Care, Inc.
  • 9.59. Theracos, Inc.
  • 9.60. Transdermal Specialties, Inc.
  • 9.61. Valeritas
  • 9.62. ViaCyte, Inc. (formerly Novocell)
  • 9.63. Vivus, Inc.
  • 9.64. vTv Therapeutics (formerly TransTech Pharma)
  • 9.65. Ypsomed Holding
  • 9.66. Zealand Pharma

INDEX OF FIGURES

  • Figure 2.1: Worldwide Diabetes Cases, 2015 and 2035
  • Figure 2.2: Worldwide Prevalence of Diabetes (%) in Adults (20-79 Years), 2013
  • Figure 2.3: Annual Number of New Cases of Diagnosed Diabetes Among U.S. Adults Aged 18-79 Years, 1980-2012
  • Figure 2.4: New Adult Cases of Diabetes Diagnosed in the U.S., 2012
  • Figure 2.5: Diagnosed and Undiagnosed Diabetes by Age in the U.S., 2013
  • Figure 2.6: Percentage of U.S. Adults Diagnosed Diabetes by State, 2013
  • Figure 2.7: Number of Deaths from Diabetes by Age in the U.S., 2013
  • Figure 2.8: Number of Diabetes Deaths by Race and Sex in the U.S., 2013
  • Figure 2.9: Mean Diabetes Healthcare-Related Expenditures Per Adult (20-79 Years) with Diabetes (USD), 2013
  • Figure 2.10: How Diabetes Dollars are Spent in the U.S.
  • Figure 3.1: Maintenance of Normal Blood Sugar Levels
  • Figure 3.2: Prevalence of Self-Reported Obesity (BMI 3 30) Among U.S. Adults, 2013
  • Figure 3.3: Prevalence of Obesity Among Adults in the U.S., 2012
  • Figure 3.4: Percentage of Obese Children and Adolescents in the U.S., 1999-2012
  • Figure 4.1: Sales Forecast for the Global Diabetes Drug Market, 2012-2019
  • Figure 4.2: Sales Forecast for the U.S. Diabetes Drug Market, 2012-2019
  • Figure 4.3: Percentage of U.S. Diabetics Taking Medications, 2010-2012
  • Figure 4.4: U.S. Non-Insulin Anti-Diabetic Drug Market by Volume, 2014
  • Figure 5.1: Global Non-Insulin Anti-Diabetes Prescriptions by Drug Class, 2014
  • Figure 5.2: Global Non-Insulin Anti-Diabetes Sales by Drug Class, 2014
  • Figure 5.3: GLP-1 Market Share by Brand, 2014
  • Figure 5.4: GLP-1 Market Share of Key Players, 2014
  • Figure 5.5: DPP-4 Inhibitor Market Share by Brand, 2014
  • Figure 5.6: DPP-4 Inhibitor Market Share of Key Players, 2014
  • Figure 5.7: Overview of GLP-1 and Blood Glucose
  • Figure 5.8: Overview of DPP-4 Inhibitors and Blood Glucose
  • Figure 5.9: SGLT-2 Inhibitor Mechanism of Action
  • Figure 6.1: Worldwide Insulin Market Share (Value), 2014
  • Figure 6.2: U.S. Insulin Market Share (Value), 2014
  • Figure 6.3: Short-Acting Human Insulin Worldwide Market Share by Company, 2014
  • Figure 6.4: Rapid-Acting Insulin Worldwide Market Share by Company, 2014
  • Figure 6.5: Intermediate-Acting Human Insulin Worldwide Market Share by Company, 2014
  • Figure 6.6: Long-Acting Insulin Worldwide Market Share by Company, 2014
  • Figure 6.7: Market Share of Basal Insulins in Emerging Markets, 2014
  • Figure 6.8: Global Sales of Lantus, 2005-2014
  • Figure 6.9: Global Sales of Levemir, 2011-2014
  • Figure 6.10: Insulin Pump Market Share, 2014

INDEX OF TABLES

  • Table 2.1: Regional Estimates of the Number of Diabetes (20-79 Years) in Millions, 2015 and 2035
  • Table 2.2: Top Ten Countries with the Largest Estimated Number of Diabetics (20 to 79 Years Age Group), 2015 and 2035
  • Table 2.3: Worldwide Undiagnosed Diabetes in Adults (20-79 Years) by Region and Income Group, 2013
  • Table 2.4: Countries with the Largest Number of Deaths Attributable to Diabetes, 2013
  • Table 2.5: U.S. Population of Diagnosed Diabetics Aged 20-79 Years, 2013
  • Table 2.6: Percentage of U.S. Adults with Diagnosed Diabetes by State, 2010
  • Table 2.7: Cost of Diagnosed Diabetes in the U.S.
  • Table 2.8: Annual Cost of Care of United Healthcare Adult Members with Diabetes
  • Table 2.9: Healthcare Utilization by Diabetic Patients
  • Table 3.1: International Diabetes Federation (IDF) Diagnostic Criteria for Metabolic Syndrome
  • Table 3.2: Ethnic Specific Values for Waist Circumference in IDF's Metabolic Syndrome Criteria
  • Table 3.3: American Heart Association and National Heart, Lung, and Blood Institute (AHA/NHLBI) Diagnostic Criteria for Metabolic Syndrome
  • Table 3.4: Additional Metabolic Criteria for Research
  • Table 3.5: Ten Leading Diagnoses for Co-Morbid Chronic Diseases in the U.S.
  • Table 3.6: Prevalence of Complications Among Patients with Diabetes
  • Table 3.7: Odds Ratio of Progression to Complications Associated with Type 2 Diabetes
  • Table 3.8: Novel Risk Factors and Possible Mechanisms of the Excess Risk of Coronary Heart Disease in Type 2 Diabetes Mellitus
  • Table 3.9: Major Causes of End-Stage Renal Disease
  • Table 3.10: Clinical Recommendations for Adults with Diabetes
  • Table 3.11: Laboratory Assessment of Diabetic Vascular Disease
  • Table 3.12: Average Years Gained Free of Diabetes-Related Disease with Intensive Management
  • Table 4.1: Global R&D Spending in the Pharmaceutical Industry, 2010-2014
  • Table 4.2: Pharmaceutical Companies Ranked by Total R&D Expenditures, 2014
  • Table 4.3: Leading Therapy Classes for R&D, 2014
  • Table 4.4: Leading Disease Indications for R&D, 2014
  • Table 4.5: Cost of Clinical Trial Protocol Procedure by Endpoint Type, 2012
  • Table 4.6: Global Pharmaceutical Sales by Region and Country, 2013 and 2018 (estimated) and CAGR 2009-2013 and 2014-2018 (estimated)
  • Table 4.7: World Pharmaceutical Sales Share by Region, 2013
  • Table 4.8: Leading Ten Therapeutic Classes by Global Sales, 2010-2014
  • Table 4.9: Estimated Leading Therapy Classes by Global Sales in the Developed Market, 2018
  • Table 4.10: Estimated Leading Therapy Classes by Global Sales in the Pharmerging Market, 2018
  • Table 4.11: Leading Therapeutic Classes by U.S. Sales, 2010-2014
  • Table 4.12: Top Selling Drugs Worldwide by Sales, 2014
  • Table 4.13: Top Selling Drugs in the U.S. by Sales, 2014
  • Table 4.14: Top Ten Global Pharmaceutical Companies by Global Sales, 2014
  • Table 4.15: Worldwide Anti-Diabetes (Insulin and Non-Insulin) Drug Market, 2012-2019
  • Table 4.16: U.S. Anti-Diabetes (Insulin and Non-Insulin) Drug Market, 2012-2019
  • Table 4.17: Anti-Diabetic Therapy Markets, 2014
  • Table 4.18: Top Ten Branded Anti-Diabetics by Sales Worldwide, 2014
  • Table 4.19: Top Ten Branded Anti-Diabetics by Monthly Prescriptions Worldwide, 2014
  • Table 4.20: American College of Physicians 2012 Practical Guideline for the Use of Anti-Diabetes Drugs for Type 2 Diabetes
  • Table 4.21: Summary of Glucose-Lowering Interventions as Monotherapy
  • Table 5.1: Classes of Non-Insulin Hypoglycemic Agents
  • Table 5.2: Branded Non-Insulin Hypoglycemic Drugs Used to Treat Type 2 Diabetes in the U.S., 2014
  • Table 5.3: Relative Efficacy of Diabetes Drugs
  • Table 5.4: Worldwide Non-Insulin Anti-Diabetes Drug Market, 2012-2019
  • Table 5.5: U.S. Non-Insulin Anti-Diabetes Drug Market, 2012-2019
  • Table 5.6: Diabetes Drugs Approved for U.S. Market, 2014 and 2015
  • Table 5.7: GLP-1 Drug Revenues in 2014
  • Table 5.8: DPP-4 Inhibitor Revenues in 2014
  • Table 5.9: SGLT-2 Inhibitor Revenues in 2014
  • Table 5.10: Fixed-Dose Oral Anti-Diabetes Drug Combinations
  • Table 5.11: GLP-1 Agonist Pipeline: Selected Drugs in Development
  • Table 5.12: DPP-IV Inhibitor Pipeline: Selected Drugs in Development
  • Table 5.13: SGLT-2 Inhibitor Pipeline: Selected Drugs in Development
  • Table 5.14: Fixed-Dose Combination Drugs with SGLT-2 Inhibitor: Selected Drugs in Development
  • Table 5.15: Summary of Emerging Non-Insulin Anti-Diabetes Drug Categories
  • Table 6.1: Value Market Shares of Animal, Human and Modern Insulin, 1995-2014
  • Table 6.2: Worldwide Insulin Market, 2012-2019
  • Table 6.3: Worldwide Insulin Sales and Market Share by World Region, 2014
  • Table 6.4: U.S. Insulin Market, 2012-2019
  • Table 6.5: Key Drivers of the Type 2 Diabetes Insulin Market, 2014
  • Table 6.6: Worldwide Insulin Market by Type (% Market Value), 2014
  • Table 6.7: Worldwide Insulin Sales and Value Market Share by Company, 2014
  • Table 6.8: U.S. Insulin Sales and Value Market Share by Company, 2014
  • Table 6.9: Insulins on the U.S. Market
  • Table 6.10: Pharmacokinetics of Therapeutic Insulins on the U.S. Market
  • Table 6.11: Comparison of Recommendations from Existing Guidelines
  • Table 6.12: Pharmacokinetics of Short-Acting Human Insulins
  • Table 6.13: Short-Acting Human Insulin Worldwide Market Revenues, 2011-2014
  • Table 6.14: Pharmacokinetics of Rapid-Acting Insulins
  • Table 6.15: Rapid-Acting Insulin Worldwide Market Revenues, 2011-2014
  • Table 6.16: Pharmacokinetics of Intermediate-Acting Insulins
  • Table 6.17: Intermediate-Acting Human Insulin Worldwide Market Revenues, 2011-2014
  • Table 6.18: Pharmacokinetics of Long-Acting Insulins
  • Table 6.19: Long-Acting Insulin Worldwide Market Revenues, 2011-2014
  • Table 6.20: Pharmacokinetics of Insulin Mixtures
  • Table 6.21: A Comparison of Existing Insulin Delivery Devices
  • Table 6.22: Insulin Pens
  • Table 6.23: Estimated Worldwide Demand for Insulin Pens by Volume, 2013-2018
  • Table 6.24: Injection Aids
  • Table 6.25: Jet Injectors
  • Table 6.26: Control Averages by Treatment
  • Table 6.27: Reduced Risk for Various Diseases When Blood Glucose is Near Normal
  • Table 6.28: Leading Insulin Pump Manufacturers
  • Table 6.29: Comparison of Current External Insulin Pumps on the Market
  • Table 6.30: Insulin Infusion Sets
  • Table 6.31: Worldwide Insulin Pump Market, 2013-2019
  • Table 7.1: Advantages and Disadvantages of Newer Type 2 Diabetes Therapies
  • Table 7.2: Cells of the Pancreas
  • Table 8.1: BRIC Countries, Percentage of GDP Spent on Healthcare, 2013
Back to Top